Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Pituitary Adenoma | Research

Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study

Authors: Maryam Dehghani, Zahra Davoodi, Farahnaz Bidari, Amin Momeni Moghaddam, Davood Khalili, Hooman Bahrami-Motlagh, Elena Jamali, Shahram Alamdari, Farhad Hosseinpanah, Mehdi Hedayati, Majid Valizadeh

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Regarding the inconclusive results of previous investigations, this study aimed to determine the association between pathology, as a possible predictor, with remission outcomes, to know the role of pathology in the personalized decision making in acromegaly patients.

Methods

A retrospective cohort study was performed on the consecutive surgeries for growth hormone (GH) producing pituitary adenomas from February 2015 to January 2021. Seventy-one patients were assessed for granulation patterns and prolactin co-expression as dual staining adenomas. The role of pathology and some other predictors on surgical remission was evaluated using logistic regression models.

Results

Among 71 included patients, 34 (47.9%) patients had densely granulated (DG), 14 (19.7%) had sparsely granulated (SG), 23 (32.4%) had dual staining pituitary adenomas. The remission rate was about 62.5% in the patients with SG and DG adenomas named single staining and 52.2% in dual staining groups. Postoperative remission was 1.53-folds higher in the single staining adenomas than dual staining-one (non-significant). The remission rate was doubled in DG group compared to two other groups (non-significant). By adjusting different predictors, cavernous sinus invasion and one-day postoperative GH levels decreased remission rate by 91% (95% CI: 0.01–0.67; p = 0.015) and 64% (95% CI: 0.19–0.69; p < 0.001), respectively. Responses to the medications were not significantly different among three groups.

Conclusion

Various pathological subtypes of pituitary adenomas do not appear to have a predictive role in estimating remission outcomes. Cavernous sinus invasion followed by one-day postoperative GH is the strongest parameter to predict biochemical remission.
Literature
20.
go back to reference Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. EndocrPathol. 2008;19(2):82–91. https://doi.org/10.1007/s12022-008-9029-z.CrossRef Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. EndocrPathol. 2008;19(2):82–91. https://​doi.​org/​10.​1007/​s12022-008-9029-z.CrossRef
28.
go back to reference Bonneville F, Rivière LD, Petersenn S, Bevan J, Houchard A, Sert C, et al. PRIMARYS Study group. MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: a PRIMARY posthoc analysis. Eur J Endocrinol. 2018: EJE-18-0254.R2. https://doi.org/10.1530/EJE-18-0254. Bonneville F, Rivière LD, Petersenn S, Bevan J, Houchard A, Sert C, et al. PRIMARYS Study group. MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: a PRIMARY posthoc analysis. Eur J Endocrinol. 2018: EJE-18-0254.R2. https://​doi.​org/​10.​1530/​EJE-18-0254.
34.
go back to reference Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr (2013) Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metabol 98(8):3190–3198. Https ://doi.org/https://doi.org/10.1210/jc.2013-1036. Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA Jr (2013) Endoscopic vs microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metabol 98(8):3190–3198. Https ://doi.org/https://​doi.​org/​10.​1210/​jc.​2013-1036.
37.
go back to reference De Marinis L, Zuppi P, Valle D, Mancini A, Bianchi A, Lauriola L, et al. A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin. HormMetab Res. 2002;34(03):137–43. https://doi.org/10.1055/s-2002-23197.CrossRef De Marinis L, Zuppi P, Valle D, Mancini A, Bianchi A, Lauriola L, et al. A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin. HormMetab Res. 2002;34(03):137–43. https://​doi.​org/​10.​1055/​s-2002-23197.CrossRef
39.
40.
go back to reference Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. EndocrRelat Cancer. 2003;10(4):611–9. https://doi.org/10.1677/erc.0.0100611.CrossRef Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G. Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. EndocrRelat Cancer. 2003;10(4):611–9. https://​doi.​org/​10.​1677/​erc.​0.​0100611.CrossRef
42.
go back to reference Goldblum JR, Lamps LW, McKenney JK, Myers JL, editors. Rosai and Ackerman's surgical pathology. 11th ed. Philadelphia: Elsevier; 2018. Goldblum JR, Lamps LW, McKenney JK, Myers JL, editors. Rosai and Ackerman's surgical pathology. 11th ed. Philadelphia: Elsevier; 2018.
43.
go back to reference Yu R. Neuroendocrine Tumor Syndromes. In: Jameson JL, De Groot LJ, De Kretser DM, Giudice LC, Grossman AB, Melmed S, et al., editors. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia: Saunders; 2016. p. 2609. Yu R. Neuroendocrine Tumor Syndromes. In: Jameson JL, De Groot LJ, De Kretser DM, Giudice LC, Grossman AB, Melmed S, et al., editors. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia: Saunders; 2016. p. 2609.
44.
go back to reference Asa SL. American Registry of Pathology, Armed Forces Institute of Pathology. In: Tumors of the Pituitary Gland. Washington, DC: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology; 2011. Asa SL. American Registry of Pathology, Armed Forces Institute of Pathology. In: Tumors of the Pituitary Gland. Washington, DC: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology; 2011.
Metadata
Title
Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study
Authors
Maryam Dehghani
Zahra Davoodi
Farahnaz Bidari
Amin Momeni Moghaddam
Davood Khalili
Hooman Bahrami-Motlagh
Elena Jamali
Shahram Alamdari
Farhad Hosseinpanah
Mehdi Hedayati
Majid Valizadeh
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00850-2

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.